| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.METABOL.2006.12.001 |
| P698 | PubMed publication ID | 17378999 |
| P2093 | author name string | Sadao Wakabayashi | |
| Yoshimasa Aso | |||
| Toshihiko Inukai | |||
| Kohzo Takebayashi | |||
| Mariko Suetsugu | |||
| P2860 | cites work | RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin | Q34377294 |
| P433 | issue | 4 | |
| P921 | main subject | patient | Q181600 |
| type 2 diabetes | Q3025883 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 451-458 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Metabolism | Q15764354 |
| P1476 | title | Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. | |
| P478 | volume | 56 |
| Q36071108 | Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque |
| Q56656927 | Adipokine update – neue Moleküle, neue Funktionen |
| Q38357078 | Adipokines and their receptors: potential new targets in cardiovascular diseases. |
| Q38188874 | Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease |
| Q36766658 | Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis |
| Q45177094 | Degradation of proinsulin C-peptide in kidney and placenta extracts by a specific endoprotease activity |
| Q34699263 | Effect of periodontal treatment on adipokines in type 2 diabetes |
| Q47165590 | Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects |
| Q47855072 | Epicardial adipose tissue and coronary artery calcification in diabetic and nondiabetic end-stage renal disease patients |
| Q39884962 | Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function |
| Q30421757 | Expression and regulation of nampt in human islets |
| Q24312815 | Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity |
| Q38282408 | Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM). |
| Q36950161 | Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients |
| Q34929150 | Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. |
| Q47673405 | Increased visfatin and leptin in pregnancies complicated by pre-eclampsia |
| Q34089724 | Inflammation, a Link between Obesity and Cardiovascular Disease |
| Q36409227 | Inflammatory mechanisms in the regulation of insulin resistance |
| Q42145401 | Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells |
| Q39018610 | Investigating interactions between epicardial adipose tissue and cardiac myocytes: what can we learn from different approaches? |
| Q51811114 | Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. |
| Q84097680 | Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia |
| Q34485791 | Membrane raft–lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin |
| Q91137781 | Mitochondrial regulation of diabetic vascular disease: an emerging opportunity |
| Q89767909 | New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients |
| Q38959459 | Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension |
| Q35581515 | Nicotinamide Phosphoribosyltransferase in Human Diseases |
| Q36014103 | Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain. |
| Q27021307 | Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women |
| Q35962096 | Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients |
| Q34236254 | Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients |
| Q87239423 | Relationship between serum visfatin levels and coronary slow-flow phenomenon |
| Q46885225 | Serum levels of the adipokine visfatin are increased in pre-eclampsia |
| Q38906596 | Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: An Egyptian study |
| Q90547724 | Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris |
| Q49379342 | Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction |
| Q37700130 | The Determinants of Leptin Levels in Diabetic and Nondiabetic Saudi Males. |
| Q47241460 | The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery |
| Q34022211 | The role of adipose tissue and adipokines in obesity-related inflammatory diseases |
| Q46137989 | Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis |
| Q35018928 | Visfatin as a novel mediator released by inflamed human endothelial cells |
| Q34071913 | Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity |
| Q37864255 | Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review |
| Q39777377 | Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent manner. |
| Q33939122 | Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes |
| Q43106569 | Visfatin is upregulated in type-2 diabetic rats and targets renal cells |
| Q45981888 | Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. |
| Q39593990 | Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells |
| Q37719753 | Visfatin, glucose metabolism and vascular disease: a review of evidence. |
| Q39882720 | Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. |
| Q34235479 | Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells |
| Q36970010 | Visfatin/Nampt: an adipokine with cardiovascular impact |
| Q42727741 | Visfatin/PBEF/Nampt: A New Cardiovascular Target? |
| Q90664709 | Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome |
| Q28577873 | Visfatin: a new player in mesangial cell physiology and diabetic nephropathy |
Search more.